Status:
UNKNOWN
Rheumatoid Arthritis-associated Interstitial Lung Disease Definition
Lead Sponsor:
Centre Hospitalier Universitaire de Liege
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Rheumatoid Arthritis-Associated Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective multicenter study in southern Belgium to determine the prevalence and incidence of interstitial lung disease in patients with rheumatoid arthritis (RA).
Detailed Description
This is a prospective multi-centric longitudinal study of the prevalence and incidence of pulmonary diseases in patients with RA. During one year, patients with a RA diagnosis (according to the crite...
Eligibility Criteria
Inclusion
- Diagnosis of rheumatoid arthritis according to the criteria of the American Society of Rheumatology
- Age \> 18 years
- Willing to participate in the study and sign the informed consent form (ICF) of participants or their legal authorized representative
- RAIDbio subcohort : available data for one of the following analysis of biomarkers: volatile organic compounds, induced sputum or blood markers
- RAIDomix : available data for high resolution computed tomography of the chest
Exclusion
- none
Key Trial Info
Start Date :
November 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06184893
Start Date
November 20 2023
End Date
October 1 2025
Last Update
December 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Liege
Liège, Belgium, 4000